A Randomized, Parallel-group, Double-blind, Double-dummy, Active-controlled, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids
Phase of Trial: Phase III
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Vilaprisan (Primary)
- Indications Uterine leiomyoma
- Focus Registrational; Therapeutic Use
- Acronyms ASTEROID 5
- Sponsors Bayer
- 16 Nov 2017 Planned primary completion date changed from 31 May 2020 to 28 Sep 2021.
- 29 Aug 2017 Accrding to a Bayer media release, first U.S. patient has been enrolled.
- 03 Jul 2017 According to a Bayer media release, the first patient has been enrolled in this trial.